Joint modelling of competing risks of drug withdrawal and quality of life in epilepsy trials.

Add to your list(s) Download to your calendar using vCal

• Paula Williamson, Centre for Medical Statistics and Health Evaluation, University of Liverpool
• Tuesday 17 April 2007, 14:30-15:30
• Large Seminar Room, 1st Floor, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge.

If you have a question about this talk, please contact nikolaos.demiris.

The International League Against Epilepsy has recommended retention time, defined as the time to withdrawal of the randomised drug or addition of another, be one of the primary endpoints for clinical trials of anti-epileptic drugs (AEDs). Patients may decide to withdraw from such treatment because of intolerable side effects or poor seizure control. Further, quality of life (QoL) is increasingly recognised as an important outcome in epilepsy and a significant proportion of patients report emotional and social impairments as a consequence of the AEDs and their epilepsy. There is a concern that these impairments may worsen over time. However, in the presence of a potentially informative event of AED withdrawal, modelling longitudinal QoL profiles alone may be misleading. The aim of this work is to simultaneously investigate the differential treatment effects on competing risks of drug withdrawal and quality of life in newly-diagnosed patients with epilepsy.

Standard methods for joint modelling of longitudinal and survival data have one failure type and an assumption of independent censoring. In this study we consider joint modelling of the competing risks (dependent censoring) of drug withdrawal and the repeated measurements of quality of life. We fit a cause-specific hazards model to allow for competing risks, with a separate association parameter for each AED withdrawal reason, and a combined analysis is undertaken. We present results on the gain from a combined analysis over the approach fitting separate models.

Acknowledgment: This work is funded by MRC Grant G0400615

This talk is part of the MRC Biostatistics Unit Seminars series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• BHRU Annual Lecture 2015
• BHRU Annual Lecture 2016
• Biology
• Cambridge Centre for Data-Driven Discovery (C2D3)
• Cambridge Immunology
• Cambridge talks
• Cardiovascular Epidemiology Unit Special Seminars
• Chris Davis' list
• Department of Public Health and Primary Care
• Graduate-Seminars
• Interested Talks
• Large Seminar Room, 1st Floor, Institute of Public Health, University Forvie Site, Robinson Way, Cambridge
• Life Sciences
• Life Sciences
• ME Seminar
• MRC Biostatistics Unit Seminars
• Primary Care
• PublicHealth@Cambridge
• Trust & Technology Initiative - interesting events
• bld31
• my_list
• ndk22's list
• ob366-ai4er
• other talks
• primary care
• rp587

Note that ex-directory lists are not shown.